Theralase Technologies Inc. (TSXV:TLT)

Market Cap	80.83M +25.5%
Revenue (ttm)	1.00M +1.5%
Net Income	-4.35M
EPS	-0.02
Shares Out	265.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	193,015
Average Volume	233,403
Open	0.3000
Previous Close	0.3100
Day's Range	0.2900 - 0.3050
52-Week Range	0.1450 - 0.3600
Beta	0.46
RSI	66.50
Earnings Date	Mar 20, 2026

About Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Roger Dumoulin-White
• Employees: 20
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: TLT

Financial Performance

In 2024, Theralase Technologies's revenue was 1.03 million, a decrease of -3.45% compared to the previous year's 1.07 million. Losses were -4.26 million, -6.89% less than in 2023.